Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Identifieur interne : 001599 ( Ncbi/Merge ); précédent : 001598; suivant : 001600Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Auteurs : Yoshihiro Sato [Japon] ; Jun Iwamoto ; Tomohiro Kanoko ; Kei SatohSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Alendronate (administration & dosage), Amino Acids (urine), Bone Density (drug effects), Bone Resorption (prevention & control), Calcium (blood), Drug Therapy, Combination, Ergocalciferols (administration & dosage), Female, Follow-Up Studies, Fractures, Spontaneous (prevention & control), Hip Fractures (prevention & control), Humans, Osteoporosis, Postmenopausal (prevention & control), Risk, Vitamin D Deficiency (prevention & control).
- MESH :
- chemical , administration & dosage : Alendronate, Ergocalciferols.
- chemical , blood : Calcium.
- chemical , urine : Amino Acids.
- drug effects : Bone Density.
- prevention & control : Bone Resorption, Fractures, Spontaneous, Hip Fractures, Osteoporosis, Postmenopausal, Vitamin D Deficiency.
- Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Risk.
Abstract
Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.
DOI: 10.1002/mds.20825
PubMed: 16538619
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D32
- to stream PubMed, to step Curation: 002D32
- to stream PubMed, to step Checkpoint: 002E88
Links to Exploration step
pubmed:16538619Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.</title><author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Mitate Hospital, Tagawa, Japan. y-sato@ktarn.or.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Mitate Hospital, Tagawa</wicri:regionArea><wicri:noRegion>Tagawa</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name></author><author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name></author><author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20825</idno><idno type="RBID">pubmed:16538619</idno><idno type="pmid">16538619</idno><idno type="wicri:Area/PubMed/Corpus">002D32</idno><idno type="wicri:Area/PubMed/Curation">002D32</idno><idno type="wicri:Area/PubMed/Checkpoint">002E88</idno><idno type="wicri:Area/Ncbi/Merge">001599</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.</title><author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Mitate Hospital, Tagawa, Japan. y-sato@ktarn.or.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Mitate Hospital, Tagawa</wicri:regionArea><wicri:noRegion>Tagawa</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name></author><author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name></author><author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Alendronate (administration & dosage)</term><term>Amino Acids (urine)</term><term>Bone Density (drug effects)</term><term>Bone Resorption (prevention & control)</term><term>Calcium (blood)</term><term>Drug Therapy, Combination</term><term>Ergocalciferols (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>Fractures, Spontaneous (prevention & control)</term><term>Hip Fractures (prevention & control)</term><term>Humans</term><term>Osteoporosis, Postmenopausal (prevention & control)</term><term>Risk</term><term>Vitamin D Deficiency (prevention & control)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Alendronate</term><term>Ergocalciferols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Calcium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="urine" xml:lang="en"><term>Amino Acids</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bone Resorption</term><term>Fractures, Spontaneous</term><term>Hip Fractures</term><term>Osteoporosis, Postmenopausal</term><term>Vitamin D Deficiency</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16538619</PMID><DateCreated><Year>2006</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>2006</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>924-9</MedlinePgn></Pagination><Abstract><AbstractText>Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.</AbstractText><CopyrightInformation>(c) 2006 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mitate Hospital, Tagawa, Japan. y-sato@ktarn.or.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kanoko</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Satoh</LastName><ForeName>Kei</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004872">Ergocalciferols</NameOfSubstance></Chemical><Chemical><RegistryNumber>90032-33-0</RegistryNumber><NameOfSubstance UI="C036020">deoxypyridinoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>X1J18R4W8P</RegistryNumber><NameOfSubstance UI="D019386">Alendronate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019386">Alendronate</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000596">Amino Acids</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015519">Bone Density</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001862">Bone Resorption</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004872">Ergocalciferols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005598">Fractures, Spontaneous</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006620">Hip Fractures</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015663">Osteoporosis, Postmenopausal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014808">Vitamin D Deficiency</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20825</ArticleId><ArticleId IdType="pubmed">16538619</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name></noCountry><country name="Japon"><noRegion><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001599 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001599 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16538619
|texte= Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16538619" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |